Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 03 November 2016 | By Zachary Brennan
In its annual accountability review, the UK’s Medicines & Healthcare products Regulatory Agency told the Parliamentary Under Secretary of State for Health that the UK “remained an active member of EU regulatory networks until we left the EU.”
MHRA work with the EMA has been extensive, and according to the minutes of the meeting on 20 October, “was highly valued. The MHRA was working closely with stakeholders, including industry, to fully consider all the options for regulation of medicines, devices and blood products following Brexit.”
MHRA chief executive Dr. Ian Hudson explained its close working relationship with EMA via its:
“Attendees discussed the major strategic challenges facing the MHRA. The foremost of these would be the implications for MHRA of the UK’s exit from the European Union,” the minutes said.
The agency detailed other important efforts the agency has undertaken in 2015-2016, including the signing of a Memorandum of Understanding with the Indian Central Drugs Standard Control Organisation, and its help in developing 15 World Health Organization international standards to “underpin consistent manufacture and accurate measurement of biological medicine and diagnostics, including standards for Ebola and several other ‘first in class’ materials.”
Annual Accountability Review 2015-2016
Tags: MHRA, Brexit, EU regulatory networks